SYTE.bio

📍 Boston, United States👥 10 employees💰 Last funded Jun 2021
Biotechnology Research🌐 syte.bio
Website LinkedIn
SYTE.bio is a Synthetic Biology Start-Up company developing precision DNA & RNA-based therapeutics and vaccines. The company has been incorporated as a Delaware C Corp in 2021 (SYTE.bio, Inc), and has labs & offices in Argentinas headquarter, that has been operating since 2017. SYTE.bio is pioneering the development of life-changing treatments for severe diseases and vaccines to treat and prevent diseases at the molecular and cellular level using engineered DNA, improving life through innovation. SYTE.bio’s powerful redosable DNA & RNA delivery platforms will unleash the potential of personalized genetic medicine in multiple potential applications, such as Gene Therapy (Oncology, Monogenic Diseases, Cardiovascular Diseases, Vaccines, Orphan Diseases), Cell Therapy (CAR-T Therapy, Induced Pluripotent Stem Cells (iPSC)) and Gene Editing (CRISPR/Cas, TALEN, ZFN).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in SYTE.bio?
SYTE.bio has 1 investors on record on gritt.io.
When did SYTE.bio last raise funding?
The most recent investment in SYTE.bio recorded on gritt.io was in June 2021.
What industry is SYTE.bio in?
SYTE.bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SYTE.bio based?
SYTE.bio is headquartered in Boston, United States.